T
Tzu-yin Lin
Researcher at University of California, Davis
Publications - 69
Citations - 2099
Tzu-yin Lin is an academic researcher from University of California, Davis. The author has contributed to research in topics: Drug delivery & Bladder cancer. The author has an hindex of 21, co-authored 61 publications receiving 1512 citations. Previous affiliations of Tzu-yin Lin include University of California, Berkeley & Ohio State University.
Papers
More filters
Journal ArticleDOI
A smart and versatile theranostic nanomedicine platform based on nanoporphyrin
Yuanpei Li,Tzu-yin Lin,Yan Luo,Yan Luo,Qiangqiang Liu,Qiangqiang Liu,Wenwu Xiao,Wenchang Guo,Diana Lac,Hongyong Zhang,Caihong Feng,Caihong Feng,Sebastian Wachsmann-Hogiu,Jeffrey H. Walton,Simon R. Cherry,Douglas J. Rowland,David L. Kukis,Chong-Xian Pan,Kit S. Lam +18 more
TL;DR: The use of one single polymer is demonstrated to develop a smart “all-in-one” nanoporphyrin platform that conveniently integrates a broad range of clinically relevant functions.
Journal ArticleDOI
Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment
Xiangdong Xue,Yee Huang,Ruonan Bo,Bei Jia,Hao Wu,Ye Yuan,Zhongling Wang,Zhongling Wang,Zhao Ma,Di Jing,Di Jing,Xiaobao Xu,Weimin Yu,Weimin Yu,Tzu-yin Lin,Yuanpei Li +15 more
TL;DR: A dual size/charge- transformable, Trojan-Horse nanoparticle (pPhD NP) for delivery of ultra-small, full active pharmaceutical ingredients (API) nanotheranostics with integrated dual-modal imaging and trimodal therapeutic functions shows enormous potentials to improve cancer treatment.
Journal ArticleDOI
The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.
Tzu-yin Lin,Misty D. Bear,Zhenjian Du,Kevin Foley,Weiwen Ying,James Barsoum,Cheryl A. London +6 more
TL;DR: In this paper, a novel HSP90 inhibitor, STA-9090, was evaluated against wild-type (WT) and mutant Kit in canine bone marrow-derived cultured mast cells (BMCMCs) and fresh malignant mast cells.
Journal Article
The novel HSP90 inhibitor STA-9090 exhibits activity against Kit dependent and independent malignant mast cell tumors.
TL;DR: A novel HSP90 inhibitor, STA-9090, exhibits broad activity against mast cells expressing WT or mutant Kit, suggesting it may be an effective agent in the clinical setting against mast cell malignancies.
Journal ArticleDOI
Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer.
Tzu-yin Lin,Yuanpei Li,Qiangqiang Liu,Jui Lin Chen,Hongyong Zhang,Diana Lac,Hua Zhang,Katherine W. Ferrara,Sebastian Wachsmann-Hogiu,Tianhong Li,Susan D. Airhart,Ralph W deVere White,Kit S. Lam,Chong-Xian Pan +13 more
TL;DR: A multifunctional nanoporphyrin platform that was coated with a bladder cancer-specific ligand named PLZ4 integrates photodynamic diagnosis, image-guided photodynamic therapy, photothermal therapy and targeted chemotherapy in a single procedure and served as effective triple-modality therapeutic agents against bladder cancers.